Clinical trialNCT05104853CompletedPhase 1/PHASE2Interventional

Study to Evaluate the Safety, Tolerability, PDs, and Efficacy of CNP-104 in Subjects With Primary Biliary Cholangitis

SponsorCOUR Pharmaceutical Development Company, Inc.Enrollment42Primary Biliary Cholangitis

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This study is a Phase 2a First-in-Human (FIH) clinical trial to assess the safety, tolerability, pharmacodynamics (PD), and efficacy of multiple ascending doses of CNP-104. The study consists of a 120 day primary study followed by a 20 month long-term safety and durability of response follow-up period.

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

Christopher Bowlus, MD
UC Davis
Principal InvestigatorKOL profile →
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

19 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States

Southern California Research Center
Coronado, California, United States
Om Research
Lancaster, California, United States
University of California Davis Health
Sacramento, California, United States
Peak Gastroenterology Associates
Colorado Springs, Colorado, United States
Yale School of Medicine
New Haven, Connecticut, United States
University of Florida - Hepatology Research
Gainesville, Florida, United States
Mayo Clinic Florida
Jacksonville, Florida, United States
Florida Research Institute
Lakewood Rch, Florida, United States
Gi Pros Research
Naples, Florida, United States
Cleveland Clinic - Florida
Weston, Florida, United States
Digestive Healthcare of Georgia
Atlanta, Georgia, United States
University of Chicago Medical Center
Chicago, Illinois, United States
Massachusetts General Hospital
Boston, Massachusetts, United States
Henry Ford Health System
Novi, Michigan, United States
Washington University School of Medicine in St. Louis
St Louis, Missouri, United States
Montefiore Medical Center
The Bronx, New York, United States
Duke University Medical Center
Durham, North Carolina, United States
Texas Liver Institute
San Antonio, Texas, United States
University of Virginia
Charlottesville, Virginia, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

CNP-104Placebo

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 25 Jan 2022
Primary completion: 30 Jan 2026
Completion: 30 Jan 2026
Last update posted: 10 Mar 2026
Registered enrollment: 42
Registry id: NCT05104853

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.